Bispecific Antibody Active in NRG1-Positive Pancreatic Cancer Zenocutuzumab turns in promising results in early-phase trial involving multiple solid tumors Jun 10, 2021
Combination Shows Promise in Post-Osimertinib Lung Cancer Responses in 36% with amivantamab-lazertinib, 47% with EGFR/MET resistance Jun 06, 2021
Antibody-Drug Conjugate Active in Resistant Lung Cancer Responses in 39% of EGFR inhibitor-resistant patients with patritumab deruxtecan Jun 05, 2021
Chemoimmunotherapy Tied to Better Outcomes in Advanced NSCLC PD-L1 status and age play key roles in success of combined regimen versus immunotherapy alone Jun 05, 2021
Lymph Node Findings on PET: Cancer or COVID Vaccine? Post-jab radiotracer uptake "could prompt unnecessary biopsies and treatments" May 26, 2021
Anti-PD-L1 Plus SBRT Enhances Major Responses in Early NSCLC Neoadjuvant combo needs to be validated in a larger randomized trial May 20, 2021
PD-L1 Inhibitor Thwarts Recurrence in Early Lung Cancer Risk of death, recurrence 34% lower with atezolizumab after surgery and chemo May 19, 2021
Op-Ed: Is FDA's Cigarette Ban Just Smoke and Menthols? Actually implementing a ban on menthol cigarettes and cigars could take years May 03, 2021
SBRT Safe for Cancer Patients With Multiple Metastases Late adverse events in phase I trial indicate need for extended follow-up May 03, 2021
Lung Cancer Survival Continues to Rise With Immunotherapy Twice as many patients with advanced NSCLC alive at 5 years with pembrolizumab vs chemo Apr 29, 2021
New Anti-PD1 Drugs Boost Survival in Treated Lung Cancer Questions about generalizability of results with China-developed therapies Apr 14, 2021
A Win for Nivolumab as Preoperative Therapy for Lung Cancer Pathologic CR rate 12 times higher with the addition of anti-PD-1 agent to chemo Apr 11, 2021
USPSTF Expands Lung Cancer Screening Criteria Lower age for starting, new definition of 'heavy smoker' double eligibility for screening Mar 09, 2021
Entrectinib Impresses in Certain Lung Cancers Durable responses in most patients with advanced NSCLC, active in brain mets Mar 05, 2021
New Targeted Therapies Show Promise in Cancer Selected abstracts from the ESMO Targeted Anticancer Therapies virtual meeting Mar 03, 2021
Neoadjuvant Dual ICI Leads to Clinical Benefit in Operable NSCLC More than one-third of patients achieved major pathologic response with nivolumab-ipilimumab. Feb 18, 2021
New Drug OK'd for Chemo-Induced Myelosuppression in SCLC CDK4/6 inhibitor cut the risk for severe neutropenia in small-cell lung cancer patients Feb 13, 2021
Dustin Diamond's Small Cell Lung Cancer "Saved by the Bell" actor diagnosed after exhaustive testing Feb 02, 2021
KRAS Inhibitor Continues to Impress in NSCLC Sotorasib yielded deep and durable responses in over one-third of patients Feb 01, 2021
Nab-Paclitaxel as Possible Option for Relapsed NSCLC Noninferior to docetaxel for OS, though impact on clinical practice questioned Feb 01, 2021
Should COVID-Strained Centers Hit Pause on Lung Cancer Screening? A debate on what stopping scans would do to health systems, patients Feb 01, 2021
Promising Data for Preop Checkpoint Inhibition in NSCLC Major response rate of 21%, encouraging survival with single-agent atezolizumab Jan 31, 2021
First-Ever Survival Bump in Relapsed Mesothelioma OS, PFS improved with nivolumab, but questions remain about alternatives, biomarkers Jan 30, 2021
Dual Checkpoint Blockade No Help in PD-L1-High NSCLC Single-agent pembrolizumab wins out as first-line therapy for advanced disease Jan 30, 2021
COVID Affects Cancer Care, Patients' Mental Health Studies: fewer diagnoses, more severe disease, worse outcomes, distressed patients Jan 29, 2021
Montana Oncologist Fired for Misdiagnosing, Overtreating Patients But some rally around him Jan 26, 2021
Cancer and COVID; Booze and Cancer; 'Screech' Starts Chemo News, features, and commentary about cancer-related issues Jan 21, 2021
Targeted Combo Fails in EGFR-Mutant NSCLC Osimertinib-bevacizumab no better than osimertinib alone Jan 07, 2021
Baby Boys Get Cancer From Mom During Birth Report highlights potential fetal implications of undiagnosed maternal cervical cancer Jan 06, 2021
Lorlatinib Shows 'Striking' CNS Activity in ALK Lung Cancer But unusual adverse events may hold therapy back Nov 18, 2020
CDK4/6 Inhibitor in SCLC Cuts Chemo-Induced Myelosuppression Reduced severe neutropenia and less need for supportive care with trilaciclib Oct 20, 2020
Dual Checkpoint Blockade With Some Chemo Boosts OS in NSCLC Nivolumab-ipilimumab with two cycles of chemotherapy improved survival, regardless of histology or PD-L1 status Oct 17, 2020
Drug Active in 'Undruggable' KRAS-Mutant NSCLC Responses in a third of patients, disease control rate approaching 90% Sep 20, 2020
A Closer Look at FDA Decision to Pull Lorcaserin More cancers, multiple primaries, and deaths in CAMELLIA-TIMI 61 influenced agency decision Sep 09, 2020
In Lupus, Older Age and Male Sex Raise Cancer Risk Role of most medications, though, not yet clear Aug 21, 2020
Chemo-Free Regimen Boosts OS in Mesothelioma Big advantage for nivolumab-ipilimumab in nonepithelioid tumors drives advantage over chemo Aug 09, 2020
Another ALK Drug Tops Crizotinib in First-Line NSCLC Ensartinib doubled PFS over older standard, with improved CNS activity Aug 08, 2020
COVID-19 More Deadly Than Cancer Itself? Highlights from the AACR conference on COVID-19 and cancer Jul 24, 2020
The Serious Conversation: Delivering Bad News by Telemedicine As office visits move online, clinicians discuss breaking life-changing diagnoses virtually Jul 13, 2020
